Navigation Links
SectorWatch.biz Issues MarketStats on CVBT, BSX, MDT, CXM and DNA
Date:2/14/2008

IRVINE, Calif., Feb. 14 /PRNewswire/ -- SectorWatch.biz announces the availability of MarketStats on public equities that are in the news and driving markets today.

Investors can view all of SectorWatch.biz MarketStats free of charge by visiting: http://www.SectorWatch.biz -- Click on MarketStats

Today's MarketStats on Healthcare and Biotechnology companies include: CardioVascular Bio Therapeutics, Inc. (OTC Bulletin Board: CVBT), Boston Scientific Corp. (NYSE: BSX), Medtronic Inc. (NYSE: MDT), Cardium Therapeutics Inc. (Amex: CXM) and Genentech Inc. (NYSE: DNA).

To view a complete profile on CardioVascular Bio Therapeutics, Inc., visit our financial courier StockUpTicks.com (http://www.stockupticks.com).

Our MarketStats provide snapshots and analysis on public equities making news, driving industry sectors and affecting the markets. SectorWatch.biz is powered by Market Pathways, a leader in the representation of Small Cap equities for over twenty-five years. We are your discovery zone for under-followed stocks shaping the market.

Interested investors may subscribe for FREE to our StockUpTicks newsletter featuring a treasure trove of promising companies, daily market movers and free personal investment information -- visit http://stockupticks.com/register.html. D.R. Clark of Market Pathways is a member of the National Association of Securities Dealers, CRD # 4518163.

Contact us directly to have your company featured in StockUpTicks.com or SectorWatch.biz. For D.R. Clark's perspective on personal finance and the markets visit http://www.ClarkReport.com

Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SectorWatch.biz and StockUpTicks.com are properties of Market Pathways Financial Relations, Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience. The subject companies have not always approved the statements made in this report.

This report is neither a solicitation to buy nor an offer to sell securities but is for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor, analyst or licensed broker dealer and this report is not investment advice. MP has been granted twenty thousand restricted shares of CVBT common stock by CardioVascular BioTherapeutics Inc. for preparation and distribution of this report and other services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.


'/>"/>
SOURCE SectorWatch.biz
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
2. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
3. Baxter Issues Urgent Nationwide Voluntary Recall of Heparin 1,000 Units/mL 10 and 30mL Multi-Dose Vials
4. FDA Issues Approvable Letter for LUVOX(R) CR (Fluvoxamine Maleate) Extended-Release Capsules for the Treatment of Social Anxiety Disorder (SAD) and Obsessive Compulsive Disorder (OCD)
5. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
6. CCPM Issues Statement on FDAs GIVE Initiative
7. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
8. CalbaTech Issues Update; Beginning Training for Adult Stem Cell Collections in Atlanta
9. HHS Issues First Department-Wide Report on Personalized Health Care
10. MichBio Issues 2007/8 Michigan Life Sciences Directory and Resources Guide
11. Pharmos Issues Letter to Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:4/13/2016)... -- IMPOWER physicians supporting Medicaid patients in Central ... in telehealth thanks to a new partnership with higi. ... patients can routinely track key health measurements, such as ... when they opt in, share them with IMPOWER clinicians ... retail location at no cost. By leveraging this data, ...
(Date:3/29/2016)... March 29, 2016 LegacyXChange, Inc. ... "LEGX" and SelectaDNA/CSI Protect are pleased to announce our ... in a variety of writing instruments, ensuring athletes signatures ... created collectibles from athletes on LegacyXChange will be assured ... the DNA. Bill Bollander , CEO ...
Breaking Biology News(10 mins):